Form 4: BridgeBio Director Exercises, Sells 10,000 Shares

BridgeBio Pharma Director Randal W. Scott exercised options and sold 10,000 shares of common stock on February 17, 2026, under a pre-arranged 10b5-1 plan.

Summary

• Director Randal W. Scott of BridgeBio Pharma, Inc. (BBIO) engaged in transactions on February 17, 2026.
• Scott acquired 10,000 shares of common stock by exercising stock options at an exercise price of $16.75 per share.
• Concurrently, Scott sold a total of 10,000 shares of common stock in multiple transactions.
• The sales occurred at weighted average prices of $74.3421, $75.5725, and $75.9261 per share.
• These transactions were executed pursuant to a Rule 10b5-1 sales plan adopted on June 27, 2025.
• Following these transactions, Scott directly holds 11,589 shares and indirectly holds 4,000 shares through Thinking Bench Capital LLC.
• Scott also retains 31,501 stock options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While a director sold shares, it was a pre-planned exercise-and-sell transaction, indicating liquidity management rather than a bearish outlook, and the high sale price relative to the exercise price is positive.

Positives

• The exercise of options indicates the underlying stock price is significantly above the exercise price ($74+ vs $16.75), suggesting strong appreciation.
• The transactions were conducted under a pre-arranged Rule 10b5-1 plan, which can mitigate concerns about opportunistic insider selling.

Negatives

• The sale of 10,000 shares by a director, even if pre-planned, represents a reduction in direct ownership.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving option exercises followed by sales, are common for executive compensation and liquidity management. The execution under a 10b5-1 plan suggests a pre-planned financial strategy rather than a reaction to immediate company news, which is a standard practice to avoid accusations of trading on material non-public information.

Comparison to Industry Standards

• StockSavvy.ai observes that the practice of exercising stock options and immediately selling the acquired shares is a common liquidity event for executives across various industries, particularly in biotech where compensation often includes significant equity components.
• The use of a Rule 10b5-1 plan aligns with best practices for corporate governance, similar to how executives at companies like Pfizer or Amgen manage their equity compensation to ensure compliance and transparency.

Related Party Transactions

• Indirect beneficial ownership of 4,000 shares through Thinking Bench Capital LLC, which may be a related entity to the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a director could be perceived negatively, but the pre-planned nature and option exercise context mitigate this. The high sale price relative to exercise price is positive for overall shareholder value perception.

Next Steps

• Remaining 1/3rd of stock options will vest on June 21, 2026, subject to continued board service.

Key Dates

Recommendation

The filing details a routine insider transaction involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 plan. This type of transaction is typically for liquidity or tax planning and does not signal a strong change in the director's confidence in the company's future prospects. The significant difference between the option exercise price and the sale price reflects past stock appreciation, which is positive. However, the net effect is a reduction in direct ownership, which prevents a 'buy' recommendation. Given the neutral nature of this specific filing, a 'hold' recommendation is appropriate, pending further fundamental analysis of BridgeBio Pharma.

Keywords

BridgeBio Pharma, BBIO, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Randal W. Scott, 10b5-1 Plan, Director Transaction